These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39164118)

  • 1. Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience.
    Colussi L; Dagri A; Pastore S; Tommasini A; Pin A; Taddio A
    Int J Rheum Dis; 2024 Aug; 27(8):e15295. PubMed ID: 39164118
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of JAK inhibitors in the treatment of progressive systemic sclerosis.
    Deverapalli SC; Rosmarin D
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):e328. PubMed ID: 29444362
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
    Scheinberg M; Ferreira SB
    Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
    [No Abstract]   [Full Text] [Related]  

  • 4. Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.
    Cao XY; Zhao JL; Hou Y; Wang FD; Lu ZH
    Clin Exp Rheumatol; 2020; 38(3):567-568. PubMed ID: 31820721
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
    King B; Lee AI; Choi J
    J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
    [No Abstract]   [Full Text] [Related]  

  • 6. Tofacitinib for the treatment of alopecia areata in preadolescent children.
    Craiglow BG; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
    [No Abstract]   [Full Text] [Related]  

  • 7. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
    Koga T; Sato T; Umeda M; Fukui S; Horai Y; Kawashiri SY; Iwamoto N; Ichinose K; Nakamura H; Kawakami A
    Clin Immunol; 2016 Dec; 173():147-148. PubMed ID: 27720846
    [No Abstract]   [Full Text] [Related]  

  • 9. Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
    Hu Q; Wang M; Jia J; Teng J; Chi H; Liu T; Liu HL; Cheng X; Ye J; Su Y; Sun Y; Zhou Z; Wan L; Wang Z; Wang F; Shi H; Yang C
    Ann Rheum Dis; 2020 Jun; 79(6):842-844. PubMed ID: 32079571
    [No Abstract]   [Full Text] [Related]  

  • 10. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
    Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
    Moghadam-Kia S; Charlton D; Aggarwal R; Oddis CV
    Rheumatology (Oxford); 2019 Jun; 58(6):1011-1015. PubMed ID: 30608616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful therapy of refractory cutaneous morphea with tofacitinib.
    Russo G; Dumont S; Laffitte E
    Ital J Dermatol Venerol; 2024 Aug; 159(4):469-470. PubMed ID: 38780912
    [No Abstract]   [Full Text] [Related]  

  • 15. Pregnancy outcomes following tofacitinib use for synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: Case report.
    Zhang C; Shi X; Ding Y; Lin Z; Qian T; Liu X; Hou X; Li C
    Int J Rheum Dis; 2024 Jun; 27(6):e15209. PubMed ID: 38873853
    [No Abstract]   [Full Text] [Related]  

  • 16. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
    J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of tofacitinib in IBD: A tricky puzzle.
    Beaugerie L
    United European Gastroenterol J; 2024 Jul; 12(6):658-659. PubMed ID: 38761370
    [No Abstract]   [Full Text] [Related]  

  • 18. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.
    Chen Z; Wang X; Ye S
    N Engl J Med; 2019 Jul; 381(3):291-293. PubMed ID: 31314977
    [No Abstract]   [Full Text] [Related]  

  • 19. Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: A case report and review of the literature.
    Fan Y; Yin R
    Int Immunopharmacol; 2024 Sep; 139():112762. PubMed ID: 39074417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
    Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
    Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.